The Milner Therapeutics Institute has announced Elysium Health as the latest company to become a partner in the Milner Therapeutics Consortium, which brings together the drug development capabilities of pharmaceutical companies with the ideas and know-how of Cambridge academics.
The company will also join the Institute's Innovation Board to help define and solve some of the grand challenges in health today such as early intervention to prevent avoidable chronic diseases and maintaining health over extended lifespans.
For more details see the press release on the Milner Therapeutics Institute website.